

1 **COVID-19 Serology in New York State Using a Multiplex Microsphere Immunoassay**

2

3

4 Danielle T. Hunt¹, Jennifer L. Yates^{1,2}, Karen E. Kulas¹, Kyle Carson¹, Theresa Lamson¹,
5 Valerie Demarest¹, Andrea Furuya¹, Kelly Howard¹, Mary Marchewka¹, Randy Stone¹,
6 Heidi Tucker¹, Casey Warszycki¹, Jim Yee^{3,4}, He S. Yang^{3,4}, Sabrina Racine-Brzostek^{3,4},
7 Zhen Zhao^{3,4}, Monir Ejemel⁵, Qi Li⁵, Yang Wang⁵, Sebastian Fernando⁶, Francesca La
8 Carpia⁶, Eldad A. Hod⁶, Kathleen A. McDonough^{1,2} and William T. Lee^{1,2*}.

9

10 ¹Division of Infectious Diseases, Wadsworth Center, New York State Department of
11 Health, Albany, NY, 12208 USA; ²Department of Biomedical Sciences, The School of
12 Public Health, The University at Albany, Albany, NY, 12222 USA; ³Department of
13 Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA;
14 ⁴NewYork-Presbyterian Hospital/Weill Cornell Medical Campus, New York, NY, USA;
15 ⁵MassBiologics of the University of Massachusetts Medical School, Boston, MA, 02126
16 USA; ⁶Department of Pathology and Cell Biology, Columbia University Irving Medical
17 Center, New York, NY, USA

18

19

20 Running Head: CoV-2 virus serology at NYSDOH

21

22

23 *Address Correspondence to: Dr. William T. Lee
24 David Axelrod Institute
25 The Wadsworth Center/NYSDOH
26 120 New Scotland Avenue
27 Telephone: (518) 473-3543
28 Email: William.Lee@health.ny.gov

29

30

31

32

33

34 **Footnotes**

35 ¹Abbreviations: COVID-19, coronavirus disease 2019; SARS-CoV-2, Severe acute
36 respiratory syndrome coronavirus 2, HuCOV, human endemic (seasonal) coronaviruses;
37 Ab, antibody; (DIL, Diagnostic Immunology Laboratory at the Wadsworth Center; N,
38 nucleocapsid protein; RBD, receptor-binding domain; MFI, median fluorescent intensity;
39 FDA, Food and Drug Administration; EUA, Emergency Use Authorization; MIA,
40 microsphere immunoassay

41 **Abstract**

42

43 The emergence of SARS-CoV-2, leading to COVID-19, necessitated the development of
44 new molecular and serological tests. Here, we describe a multiplexed serological assay
45 developed as the global pandemic moved into New York State in the spring of 2020. The
46 original microsphere immunoassay used a target antigen from the SARS-CoV-1 virus
47 responsible for the 2003 SARS outbreak, but evolved to incorporate multiple SARS-CoV-
48 2 protein antigens (nucleocapsid, spike and spike domains, spike and nucleocapsid
49 proteins from seasonal human coronaviruses). Besides being highly versatile due to
50 multiplex capabilities, the assay was highly specific and sensitive and adaptable to
51 measuring both total antibodies and antibody isotypes. While determining the assay
52 performance characteristics, we were able to identify antibody production patterns (e.g.,
53 kinetics of isotypes, individual variations) for total antibodies and individual antibody
54 classes. Overall, the results provide insights into the laboratory response to new serology
55 needs, and how the evolution and fine-tuning of a serology assay helped contribute to a
56 better understanding of the antibody response to SARS-CoV-2.

57 **1. Introduction**

58 The coronavirus disease 2019 (COVID-19) (1), caused by the Severe Acute Respiratory
59 Syndrome Coronavirus 2 (SARS-CoV-2)(2), is historically one of the most widespread
60 and devastating pandemics with severe health, economic, and social consequences (3,
61 4). As a newly emergent virus, knowledge of the resulting disease courses, host
62 response characteristics, and the development of diagnostic tests arose only as the
63 pandemic progressed. Still, a strong framework of information was already present
64 from prior studies on other disease-causing coronaviruses, including circulating human
65 endemic coronaviruses (HuCOV), Middle East Respiratory Syndrome virus, and the
66 closely related SARS-CoV-1 (reviewed in (5, 6)).

67 Within the past year there has been an enormous growth in the number of laboratory
68 assays designed to diagnose SARS-CoV-2 infection. These primarily rely on molecular
69 analyses for the detection of viral RNA, and, more recently, serological tests to detect
70 viral antigens and host antibodies (Abs) for the determination of prior exposure to
71 SARS-CoV-2. In particular, there are a wide variety of serology tests with different
72 performance characteristics, different target antigens, and different readouts (7). These
73 tests have clinical, surveillance, and research applications, including information about
74 the COVID-19 disease process and host immune response.

75 The impetus for this study was an exigent need for early development of molecular and
76 serological assays to meet the COVID-19 outbreak in New York State (NYS). As the
77 laboratory arm of the New York State Department of Health, the Wadsworth Center was
78 heavily engaged in assay development and early testing. The Diagnostic Immunology

79 Laboratory at the Wadsworth Center (DIL) initiated an effort to develop a serological
80 assay to identify persons exposed to the novel coronavirus. We developed an initial
81 microsphere immunoassay (MIA) using a Luminex® platform. We determined
82 performance characteristics and implemented the assay for COVID-19 serology testing
83 of sera from NYS residents. This platform is very adaptable which allows the inclusion
84 or replacement of several different target molecules. As described in this report, over
85 the course of the outbreak, we frequently assessed the testing data and made changes
86 as needed, which also helped to improve our understanding of the SARS-CoV-2
87 humoral response to infection.

88

89 **2. Results**

90 2.1 *Establishment of the MIA.*

91 The NYS SARS-CoV-2 MIA was initially conceived during the early phase of the
92 Wuhan COVID-19 outbreak (1). As no SARS CoV-2 proteins were available to us at the
93 beginning of February 2020, the first generation of the assay used the SARS-CoV-1
94 nucleocapsid (N) protein as the target antigen (8). The SARS-CoV-1 N protein, prepared
95 at the Wadsworth Center in 2003 for use in the original SARS outbreak (9), was coupled
96 to microspheres and tested using a guinea pig anti-serum reactive with SARS-CoV-1.
97 The antiserum showed high binding (Figure 1A), while serum from a nonimmune guinea
98 pig did not react. In later experiments employing SARS-CoV-2 antigens and COVID-19
99 sera, the same guinea pig anti-SARS-CoV-1 serum showed nearly equivalent binding to
100 the SARS CoV-2 N protein (Figure 1A). Likewise, COVID-19 patient sera were
101 comparably reactive with both SARS-CoV-1 and SARS-CoV-2 N proteins (Figure 1B)
102 and, MIAs using either protein as the target antigen behaved equivalently (Figure 1C).
103 The high degree of cross-reactivity between the two N antigens contrasted with our later
104 observations of differential antibody binding to the SARS-CoV-1 and SARS-CoV-2 Spike
105 proteins, as we observed little binding of the SARS-CoV-1 guinea pig serum to the SARS-
106 CoV-2 spike proteins (Figure 1D) and, conversely, reduced binding of COVID-19 sera to
107 the SARS-CoV-1 spike protein (Figure 1E and F).

108

109 2.2 *Specificity of the MIA*

110 Assay cutoffs are established as an MFI threshold to determine specimen
111 reactivity. A panel of 92 serum specimens from healthy donors, collected in 2009, were
112 tested for total antibody produced against SARS-CoV-1 N-protein and the cutoff was
113 defined as the mean median fluorescence intensities (MFI) plus three standard deviations
114 (SD) (Figure 2A). An additional 164 specimens were tested, and, of the total of 256, only
115 7% of the specimens (93% specificity) were reactive (data not shown). Considering that
116 for endemic seasonal coronaviruses (HCoV-229E, -NL63, -OC43, and -HKU1) there is
117 an estimated rate of up to 15% infections per year in a geographically close region (10),
118 we reasoned that there was little impact in the assay by antibodies to endemic
119 coronaviruses. We next tested a panel of 30 specimens collected 10-20 days post onset
120 of symptoms from patients with diagnosed non-COVID-19 respiratory illnesses, many of
121 whom had documented positive PCR tests for specific pathogens. Several of the
122 specimens in this category were reactive with the SARS-CoV-1 N protein in the first-
123 generation MIA, lowering the assay specificity to 67% (Figure 2B). The most notable
124 cross-reactive specimens were those from patients with RT-PCR-confirmed recent
125 exposure to the endemic coronavirus HCoV-NL-63 coronavirus, for which half of the
126 tested specimens had reactivity. The overall MFIs of the cross-reactive specimens,
127 including the reactive HCoV-NL-63 specimens, were lower than the majority of signals
128 from COVID-19 specimens (Figure 2C); hence, to allow for a more specific test, even at
129 the expense of sensitivity, we raised the cutoff for the assay to 6 SD above the mean MFI
130 of the healthy donor sera. At this level, when measuring total antibodies, the specificity
131 was 99.2% (N only). A second-generation MIA was later implemented and used the
132 SARS-Cov-2 N antigen and, to better capture the breadth of responses, the SARS-CoV-

133 2 receptor-binding domain (RBD) of the spike protein. The overall specificity of this assay
134 was 98.4% (N plus RBD) (Table 1). Including sera containing Abs to known pathogens or
135 autoantigens did not reduce the specificity (Table 1). For clinical test reporting, the
136 specimens with MFI values that fell between 3 SD and 6 SD of the mean MFI of the
137 normal serum specimens were listed as “Indeterminate” (Figure 2C). In the second-
138 generation MIA, that included the SARS-CoV-2 RBD, when the two target antigens gave
139 different results, the overall result was based on the most positive of either antigen (e.g.,
140 indeterminate plus reactive was reported as reactive). Subsequent analyses of the pre-
141 COVID blood donors showed that there were abundant antibodies to both the N and spike
142 antigens of the seasonal coronaviruses (Supplemental Figure 1), strongly suggesting that
143 non-acute antibodies to the seasonal coronaviruses did not cross-react with the SARS-
144 CoV-2 antigens in the MIA.

145 2.3 *Sensitivity of the MIA*

146 A broad examination of COVID-19 specimens showed that a greater number were
147 reactive as time progressed (Figure 3). Examination of total antibody reactive in the MIA,
148 regardless of using only the N antigen (Figure 3) or both the N and RBD proteins as target
149 antigens (Table 2), showed that the sensitivity of the assay slowly increased with
150 increased time between symptom onset and testing, with a sensitivity of 96.4% 26-30
151 days following symptom onset (Table 2). Notably, at the time the initial MIA (based upon
152 SARS-CoV-1 N antigen) was submitted to the Food and Drug Administration (FDA) for
153 Emergency Use Authorization (EUA), the maximum days of post symptom onset available
154 to us was 25 days, in which only 88% of the specimens had N-specific antibodies detected

155 by the MIA above the 6SD cutoff (EUA: <https://www.fda.gov/media/137541/download>).

156 Hence, the initial (FDA) published sensitivity of our N antigen MIA was 88%. Subsequent

157 testing of specimens with >30 days post symptom onset, showed that the assay could

158 detect a much higher percentage of positive specimens. For example, an analysis of

159 8659 COVID-19 convalescent sera (collected 30-50 days post symptom onset) showed

160 that the assay had a 92.2% (N antigen-reactive) sensitivity using the 6 SD cutoff,

161 compared to 95.9% using 3 SD (Table 3). This study also showed the impact of adding

162 additional antigens, such as the RBD, into the MIA. Comparison of separate reactivity to

163 the N and the RBD proteins within the same specimens showed that, while most sera

164 contained antibodies reactive with both antigens, several had reactivity only to the N

165 protein (4.2%, Table 3). Reactivity to RBD protein without reactivity to N did occur but at

166 a lower frequency (<1.2% of reactive specimens) (Table 3). When examining individual

167 specimens, although more often a high N reactivity coincided with high RBD reactivity,

168 many specimens had high Ab levels to one antigen but lower levels to the other (data not

169 shown). Our recent studies showed that by adding the complete spike antigen, or by

170 replacing the RBD with the spike antigen, the sensitivity of the MIA could be even further

171 increased (Supplementary Table 1). However, either with just the RBD or with the spike

172 antigen, the MIA performs comparably to other COVID-19 serology assays. In a study

173 looking at 500 sera, including 100 pre-COVID sera, the MIA had similar or better

174 sensitivity and specificity as three highly used commercial laboratory tests performed on

175 the Ortho Vitros, Biomerieux Vidas, or Abbot Architect platforms (Supplementary Table

176 1).

177 Although the primary MIA developed and used for clinical testing by the DIL
178 measured total antibody, the assay proved readily adaptable to both greater multiplexing
179 of antigens and to the measurement of individual Ab isotypes. For example, the study in
180 Supplementary Figure 1 shows the multiplexing capability with simultaneous
181 measurement of Abs to the N and spike antigens of the four seasonal coronaviruses and
182 the same antigens of SARS-CoV-2 (10-plex). The study shown in Supplementary Table
183 1 and 2 shows the measurement of individual Ab isotypes. The isotype MIAs exhibited
184 the same specificity as the parent total Ab MIA (Table 1) and exhibited good sensitivity
185 which increased with time after post-symptom onset (Supplementary Table 2).

186 *2.4 Isotype Switching in Response to SARS-CoV-2*

187 Figure 4A demonstrates that there is a wide range in individual production of total Ab
188 made to both the N and RBD antigens and shows that, even early on, some individuals
189 were highly reactive in the MIA. We more deeply investigated the onset of Ab production
190 by determining the kinetics and distribution of antibody classes. We assessed sera from
191 individuals at different times from onset of COVID-19 symptoms using the isotype-specific
192 version of the MIA while examining the responses to multiple SARS-CoV-2 antigens. For
193 these studies, we not only looked at reactivity to the RBD of the spike antigen, but also
194 the entire spike and its two major domains: the amino-terminal S1 subunit of the spike,
195 which contains the RBD, and the carboxy-terminal S2 subunit. Although most of the anti-
196 spike Abs appear to be directed toward S1 in most individuals, the S2 is also
197 immunogenic (Figure 4B and Supplementary Figure 2). The higher reactivity towards the
198 S1 domain, as compared to the RBD, suggests that of the S1-reactive Abs, the RBD

199 appears to be one, but not the only, focus of reactivity as measured by this assay.
200 Examination of antibody classes directed against the panel of SARS-CoV-2 target Ags
201 showed that smaller amounts of IgM antibodies were directed toward the N antigen and
202 S2 domain of the spike protein, as compared to the RBD and S1 antigens (Figure 5 and
203 Supplementary Figure 3). This was reflected both in the proportion of individuals making
204 Abs and the abundance of Abs. This contrasts with IgG production where we observed
205 similar production against all the tested antigens. Likewise, we observed IgA production
206 with all the tested antigens, with, perhaps, slightly better IgA responses to the S1/RBD
207 region of the spike (Supplementary Figure 3).

208 There is clearly individual variation, with some specimens having copious amounts of
209 antibodies and early production of antibodies. However, overall there was a progressive
210 increase of total antibodies that did not peak until after 40 days post symptom onset
211 (Figure 3). In contrast with canonical kinetics of secreted Ab isotypes, we found that IgM
212 did not significantly precede the production of IgG; indeed, a higher percentage of IgG
213 positive specimens were found at the earlier times after symptom onset, as compared to
214 IgM (Figure 5). The rapid rise of IgG can be more clearly seen when looking at serial
215 specimens from the same individual (Figure 6). We also examined the production of IgG
216 subclasses. We found a robust IgG1 response to all the target antigens that was induced
217 relatively early in the infection (Figure 7, Supplementary Figure 4). IgG3 production was
218 also robust, albeit slightly delayed. In contrast, only a small percentage of specimens
219 contained detectable IgG2 and IgG4. Detectable IgG4 production appeared to be
220 restricted to the nucleocapsid antigen (Figure 7, Supplementary Figure 4).

221 3. Discussion

222 This report describes the overall experience of the Wadsworth Center's approach
223 in developing serology testing to determine prior SARS-CoV-2 virus exposure. The test
224 was developed to address an emergency public health need in New York, which initially
225 had the highest number of COVID-19 cases in the US (11). While not the first US clinical
226 COVID-19 serology assay to receive FDA EUA, ours was the first microsphere-based
227 assay to receive EUA ((12) and EUA: <https://www.fda.gov/media/137541/download>).
228 Other MIAs have also been described for use in research studies (e.g., (13, 14)) and, for
229 clinical testing, Luminex Corp subsequently received EUA for its MIA (12). It was
230 reassuring that, despite our initial MIA being based on the SARS-CoV-1 N antigen, it
231 showed good result agreement with the first EUA ELISA, based on the SARS-CoV-2 RBD
232 target antigen, developed by the Krammer laboratory (15, 16). However, this should not
233 have been surprising, given the high degree of antigenic cross-reactivity between the N
234 antigens of the two viruses. That cross-reactivity also reflects the degree of amino acid
235 homology (90%) (8), as does the lower cross-reactivity observed between the spike
236 antigens of SARS-CoV-1 and SARS-CoV-2 (76% amino acid homology) (8).

237 Amino acid homology between the N or spike antigens of SARS-CoV-2 and their
238 counterparts of the four seasonal coronaviruses is <50% (17), and, likewise, none of the
239 common coronaviruses interfere with the SARS-CoV-2 MIA. It is interesting however,
240 that, although normal sera contain abundant antibodies to the common coronaviruses,
241 we only found significant reactivity when assessing sera from individuals recently infected
242 with respiratory viruses, including common coronaviruses. Whether this reflects induced

243 cross-reactive antigens or is a consequence of inflammation associated with the acute
244 infections, is currently unclear. It is notable that increases in antibodies reactive with
245 common coronaviruses also occur in acute COVID-19 infections. Acute respiratory
246 infection sera are not usually included when determining assay specificity, but, if
247 generalizable to other assays, the interference with the COVID response should be
248 considered when using highly sensitive tests when both HuCoV's and influenza infections
249 are prevalent. With respect to our SARS-CoV-2 MIA, these sera prompted us to raise the
250 assay threshold and sacrifice some sensitivity (ultimately, 92.2% versus 95.9% using only
251 the N antigens; 94.9% versus 97.1% using multiplexed N and RBD antigens). The
252 sensitivity is improved over that of the original assay, due to not only the addition of the
253 N antigen, but also the testing of specimen that had been collected at a later time point
254 after symptom onset. As measured by our MIA, the COVID antibody response over a
255 broad group of individuals was slower than expected, with the highest percentages of Ab-
256 positive individuals occurring after 21 days. Further, a small number of individuals did not
257 appear to make substantial amounts of antibodies in response to infection. Even at the 3
258 SD level, 2.7% of the specimens were negative in this study. It is likely that these are
259 individuals who truly failed to mount a large Ab response to the virus. In an examination
260 of >27,000 convalescent sera, we identified donors who had been tested up to 8 times
261 over a 6-month period, with certain individuals having consistently undetectable Ab levels
262 in the MIA (unpublished observations). Given that these represent convalescent
263 individuals, it appears that in some instances, COVID-19 can be resolved with minimal
264 antibody production, presumably solely through cell-mediated immunity. This conclusion
265 would be consistent with studies showing that, although neutralizing antibody plays a

266 predominant role, T cells can contribute to protection when antibody levels are suboptimal
267 (18-20).

268 Since the pandemic began, numerous serology tests have been developed and
269 implemented for both research and clinical testing. To date, over 60 individual serology
270 assays have received EUA (12). These tests measure antibodies to a variety of target
271 antigens and generally measure total antibody or IgG (with or without separate detection
272 of IgM). Most tests identify antibodies reactive with either the N antigen or a version of
273 the spike protein (RBD, S1, or full trimeric spike). However, the abundance of antibodies
274 to the N protein or spike protein are independent of each other and an individual serum
275 might have strong reactivity to one antigen with poor or absent reactivity to the other. This
276 may make result comparisons between different assays difficult. The detection of only
277 one or the other Ag reactivity is an important consideration when comparing performance
278 of assays that use different target antigens. An advantage of the MIA is that antigens can
279 be easily and routinely multiplexed. For example, we show here simultaneous
280 measurements of antibodies reactive with the N, S1, S2, RBD, trimeric spike, and
281 seasonal coronavirus N plus spike antigens in a single specimen. Examination of specific
282 antibody responses to each antigen may also be important for identifying severity
283 parameters of COVID-19. For example, Atyeo *et al* suggest that strong early Ab
284 responses to the N antigen are associated with high disease severity (21) and Ng *et al*
285 suggest that cross-reactivity to the S2 domain of the spike antigen of common
286 coronaviruses might offer some degree of protection from SARS-COV-2 infection (22).
287 Multiplexing the N and spike antigens may also be useful for distinguishing natural

288 infection from (spike-based) vaccination responses, as it would be expected that only
289 infection would lead to the presence of antibodies reactive with the N antigen. However,
290 caution should be used in solely relying upon the differential presence of anti-N and anti-
291 spike Abs. Aside from individual variation, timing of collection may be important as some
292 studies have shown that the duration of anti-N Abs is shorter than anti-spike Abs (23). In
293 these cases, spike reactivity without N antigen reactivity might mistakenly be reported as
294 a response to vaccination with a spike-based vaccine.

295 The MIA is readily adaptable to measuring responses of different Ig isotypes,
296 different specimen matrices, and high throughput analyses. For example, our laboratory
297 has used the MIA to detect IgM antibodies reactive with the SARS-CoV-2 N, RBD, and
298 full-length spike in both newborn serum and adult CSF to suggest in situ infections ((24)
299 and unpublished observations). However, isotype analyses may have their highest value
300 in delineating the stage of infection. Although the full kinetics of antibody persistence,
301 including isotypes, has yet to be determined, it might be expected that the presence of
302 IgM would be indicative of a more recent infection, whereas IgG alone might indicate
303 either a remote infection or a vaccine response. In terms of our own analyses of antibody
304 isotypes at early points after the onset of infection, we noted the early onset of robust IgG
305 production relative to a more canonical antibody induction pattern. The quick production
306 of IgG has been observed by others (25-27). The two individuals shown in Figure 6
307 showed a rapid rise in IgG reactive with both the N and RBD antigens, relative to IgM and
308 IgA. Both of those people were hospitalized and on ventilators at the time of blood
309 collection. Our results are consistent with measurements on the same two individuals as

310 reported by Yang *et al*, where IgM and IgG, also reactive with the N and RBD antigens,
311 were assessed using a different assay system (Pylon COVID-19 IgM and IgG cyclic
312 fluorescence assay) (27). That study examined a larger group and found that for most
313 individuals, IgG was detected coincidentally or prior to IgM detection and that there was
314 no significant difference associated with disease severity. This pattern, as illustrated by
315 Figure 6, resembles a canonical secondary antibody response. As opposed to B cells,
316 SARS-CoV-2 cross-reactive memory T cells, originating from prior infection with seasonal
317 coronaviruses, have been identified (28). It is tempting to speculate that these cells help
318 SARS-CoV-2-specific B cells and drive immediate antibody class switching. However, it
319 is also possible that switch and heightened production of IgG is due to the general
320 extensive inflammation caused by virus infection. It is also possible that the IgG
321 antibodies produced are of higher affinity than the IgM and thus, may be more easily
322 detectable in immunoassays.

323 Our purpose in developing the NYS COVID MIA was to engage in clinical testing
324 for COVID Abs. To that end, we have tested both clinical specimens for assessment of
325 patient responses to SARS-COV-2 and we have also tested more than 27,000 sera of
326 potential donors of convalescent plasma. The assay has been further modified to detect
327 Abs in dried blood spots and used in high throughput immunosurveillance studies to
328 monitor SARS-CoV-2 exposure in New York State (29). The MIA continues to evolve
329 through evaluation and possible addition of spike antigens from variants of concern.
330 Further, for the convalescent plasma screening effort, we currently are aligning the MIA
331 Index values with virus neutralization values to better identify “high titer” neutralizing

332 plasma. Finally, our future efforts will include validation of the MIA using standardized
333 sera, including the WHO International Standard ([https://www.nibsc.org/documents/ifu/20-](https://www.nibsc.org/documents/ifu/20-136.pdf)
334 [136.pdf](https://www.nibsc.org/documents/ifu/20-136.pdf)), so that results can be harmonized and reported as quantitative Binding Antibody
335 Units.

336

337 **4. Materials and Methods**

338 *4.1. COVID-19 Serum Samples*

339 Studies were performed on sera from deidentified specimens submitted to the New York
340 State Department of Health in response to a broad request for assay development and
341 validations. The request was initially made prior to and just following the first reported
342 COVID-19 case in New York (March 1, 2020). The following institutions submitted serum
343 specimens after RT-PCR confirmation of SARS-CoV-2 infection: Northwell Hospital
344 Systems, University of Rochester Medical Center, Columbia University Medical Center,
345 New York Presbyterian/Weill Cornell Medical Center, New York Presbyterian Hospital
346 (NYPH)/Columbia University (CUMC) and Weill Cornell Medical Center (WCMC), and
347 Mount Sinai Health System. These submitted specimens were “early acute” (collected 1-
348 25 days post onset of symptoms). Some acute specimens (collected 1-25 days post onset
349 of symptoms) were from COVID-19 hospitalized individuals at NYPH/WCMC. Additional
350 specimens, obtained from the New York Blood Center, were sera obtained from healthy,
351 convalescent patients who had recovered from COVID-19 >14 days prior to serum
352 collection. These specimens were from individuals volunteering to be tested as potential
353 donors of plasma for passive Ab transfer. All specimens were stored at 4°C until testing
354 was completed (<1 week) and transferred to -80°C for long-term storage. Aliquots were
355 made to minimize freeze-thaw. All testing and archiving of human specimens were done
356 under a declared New York State Public Health Emergency and also approved by
357 NYSDOH Institutional Review Board (IRB 20-021). Guinea pig antiserum reactive with
358 SARS-CoV-1 was purchased from BEI Resources (Manassas, VA).

359 4.2 *Non-COVID-19 Serum Samples*

360 Specificity and control serum panels were deidentified specimens consisting of 1) an
361 equal representation from presumed healthy individuals and received prior to 2019 that
362 were obtained from (downstate New York) the New York Blood Center or (upstate New
363 York) the American Red Cross; 2) positive identification for known pathogens or
364 autoantigens and obtained through purchase, donation, or submission for clinical testing;
365 and, 3) acute phase (non-COVID-19) respiratory infection obtained from NYPH/WCMC .
366 For the last, where indicated, the agent of infection was identified using molecular testing.

367 4.3 *Reagents*

368 For MIAs, wash buffer and phosphate buffered saline pH 7.4, 0.05% sodium azide (PBS-
369 TN) were purchased from Sigma (Sigma Aldrich, St. Louis, MO). Chemicals, 1-ethyl-3-(3-
370 dimethylaminopropyl) carbodiimide hydrochloride (EDC) and N-hydroxysulfosuccinimide
371 (sulfo-NHS), were supplied by Pierce Chemicals (Pierce, Rockford, IL). Microspheres,
372 calibration microspheres, and sheath fluid were obtained from Luminex Corporation
373 (Luminex Corp., Austin, TX). R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat
374 anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-
375 human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased
376 (Southern Biotech). Recombinant SARS-CoV-2 nucleocapsid and spike S2 domain were
377 purchased (Native Antigen, Oxfordshire, UK). Recombinant nucleocapsid and spike
378 antigens from the common human coronaviruses (OC43, 229E, HKU-1, NL-63) were
379 purchased (Native Antigen, Oxfordshire, UK). Recombinant SARS-CoV-2 RBD and spike
380 S1 domain were provided by MassBiologics (Boston, MA), and produced as described

381 below. Recombinant SARS-1 nucleocapsid was produced at the Wadsworth Center as
382 described below. For some experiments, SARS CoV-2 RBD was also a kind gift from Dr.
383 Florian Krammer, (Mount Sinai Health System). SARS-CoV-1 spike proteins were
384 purchased from BEI Resources (Manassas, VA).

385 4.4 *Recombinant Antigens*

386 The amino-acid sequence of the SARS-CoV-2 S glycoprotein sequence (GeneBank:
387 MN908947) were used to design a codon-optimized version for mammalian cell
388 expression. The synthetic gene encoding the Receptor Binding Domain (RBD) a.a. 319-
389 541 and S1 subunit a.a. 1-604 of the S glycoproteins were cloned into pcDNA 3.1 Myc/His
390 in-frame with c-Myc and 6-histidine epitope tags that enabled detection and purification.
391 The cloned genes were sequenced to confirm that no errors had accumulated during the
392 cloning process. All constructs were transfected into Expi293 cells using ExpiFectamine
393 293 Transfection Kit (Thermo Fisher), and recombinant proteins were purified by
394 immobilized metal chelate affinity chromatography using nickel-nitrilotriacetic acid (Ni-
395 NTA) agarose beads. Proteins were eluted from the columns using 250 mmol/L imidazole
396 and then dialyzed into phosphate-buffered saline (PBS), pH 7.2 and checked for size and
397 purity by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). For
398 production of the recombinant SARS-CoV-1 Nucleocapsid protein, a cDNA copy of the N
399 gene of SARS-CoV was produced by reverse transcription-PCR of RNA purified from
400 Vero E6 cells that had been infected with SARS-CoV (strain Urbani; GenBank accession
401 number AY278741). The N gene cDNA was ligated into the bacterial expression vector
402 pET-28a(+) (Novagen (Merck-Millipore) Burlington,MA) for expression of carboxy-

403 terminal His6-tagged full-length N protein. Following induction in RosettaTM
404 BL21(DE3)pLysS E. coli cells (Novagen (Merck-Millipore) Burlington, MA), his-tagged N
405 protein was purified by metal chelation chromatography on a Ni-NTA column (Novagen
406 (Merck-Millipore) Burlington, MA). The purified N protein migrated in SDS-PAGE in accord
407 with its predicted molecular mass of 47.1 kDa and was estimated to be greater than 98%
408 pure.

409 4.5. *Microsphere Immunoassay (MIA)*

410 Specimens were assessed for the presence of reactive antibodies using an MIA modified
411 from a previously described procedure (30). Briefly, recombinant antigens were covalently
412 linked to the surface of fluorescent microspheres (Luminex Corporation, Austin, TX).
413 Serum samples (25 μ L at 1:100 dilution) and antigen-conjugated microspheres (25 μ L at
414 5×10^4 microspheres/mL) were mixed and incubated 30 minutes at 37°C before washing
415 and further incubation with phycoerythrin (PE)-conjugated secondary antibody. The PE-
416 conjugated antibodies were chosen to specifically recognize, as indicated, total antibodies
417 (pan-Ig), or, individually IgM, IgA, IgG, IgG1, IgG2, IgG3, IgG4. After washing and final
418 resuspension in buffer, the samples were analyzed on a FlexMap 3D analyzer using
419 xPONENT software, version 4.3 (Luminex Corporation, Austin, TX).

420 4.6 *High-throughput Instrument Detection of Antibodies to SARS-CoV-2*

421 Specimens were assessed for the presence of reactive antibodies using: 1) the Ortho-
422 Clinical Diagnostics (Rochester, NY) Vitros anti-SARS-CoV-2 IgG chemiluminescent
423 immunoassay; 2) the Abbott Laboratories (Abbott Park, IL) SARS-CoV-2 IgG

424 chemiluminescent microparticle immunoassay); 3) the bioMerieux (Durham, North
425 Carolina) VIDAS SARS-COV-2 IgG immunoassay. The Abbott Laboratories SARS-CoV-
426 2 IgG assay is a qualitative chemiluminescence test that we performed on the Abbott
427 Architect i1000SR automated immunoassay analyzer. The target antigen is the SARS-
428 CoV-2 N protein and only IgG antibodies were measured. Testing was performed in
429 accordance with the manufacturer's instructions using undiluted serum. The FDA EUA
430 listed performance characteristics are: Sensitivity, 100% (95.8%- 100%); Specificity,
431 99.6% (99.0% - 99.9%). The Ortho-Clinical Diagnostics anti-SARS-CoV-2 IgG assay is a
432 qualitative chemiluminescence test that we performed on the Ortho Vitros 5600
433 automated immunoassay analyzer. The target antigen is the S1 subunit of the SARS-
434 CoV-2 spike protein and only IgG antibodies were measured. Testing was performed in
435 accordance with the manufacturer's instructions using undiluted serum. The FDA EUA
436 listed performance characteristics are: Sensitivity, 90.0% (76.9% - 96.0%); Specificity,
437 100% (99.1% - 100%). The bioMerieux VIDAS SARS-COV-2 IgG immunoassay is a
438 qualitative enzyme-linked fluorescence assay that we performed on the Vidas-3
439 automated analyzer. The target antigen is the RBD of the SARS-CoV-2 spike protein
440 and only IgG antibodies were measured. Testing was performed in accordance with the
441 manufacturer's instructions using undiluted serum. The FDA EUA listed performance
442 characteristics are: Sensitivity, 100% (88.3 - 100%); Specificity, 99.9% (99.4% - 100%).

443 *4.7 Reporting of Statistical Methods*

444 All graphs and statistical analyses to determine Spearman's rank correlation coefficients
445 were done using Prism 9.0 (Graphpad, San Diego, CA). Spearman's correlations were
446 calculated using all complete pairs of variables in the dataset.

447

448 **6. Acknowledgments.**

449 The authors would like to acknowledge and thank the following Wadsworth Center
450 laboratory members for their expert technical assistance: June Chan, Margaux Hales,
451 Colleen Walsh, Geraldine Quinones, Brian Grimwood. We thank Dr. Lili Kuo her advice
452 and insights on the expression of viral proteins. We especially thank Drs. Susan Wong
453 and Paul Masters for their helpful advice and their critical reading of this manuscript and
454 Dr. Steven Spitalnik for support and advice. We would like to acknowledge the
455 Wadsworth Center core facilities that contributed to this work: WC Tissue Culture and
456 Media Core and the WC Sequencing Core.

457

458 **7. Funding Sources**

459 The authors have no conflicting interests relevant to this study. This work was performed
460 in part under a Project Award Agreement from the National Institute for Innovation in
461 Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award
462 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards
463 and Technology. Additional support was provided by a grant (P20-000271) from the New
464 York Community Trust. A portion of the work described in this publication was supported

465 by Cooperative Agreement Number NU50CK000516 from the Centers of Disease Control
466 and Prevention. Its contents are solely the responsibility of the authors and do not
467 necessarily represent the official views of the Centers for Disease Control and Prevention.

468

469 **8. References**

470 1. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of
471 global health concern. *Lancet*. 2020;395(10223):470-3.

472 2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia
473 outbreak associated with a new coronavirus of probable bat origin. *Nature*.
474 2020;579(7798):270-3.

475 3. Nicola M, Alsaifi Z, Sohrabi C, Kerwan A, Al-Jabir A, Iosifidis C, et al. The socio-
476 economic implications of the coronavirus pandemic (COVID-19): A review. *Int J Surg*.
477 2020;78:185-93.

478 4. Mofijur M, Fattah IMR, Alam MA, Islam A, Ong HC, Rahman SMA, et al. Impact
479 of COVID-19 on the social, economic, environmental and energy domains: Lessons
480 learnt from a global pandemic. *Sustain Prod Consum*. 2021;26:343-59.

481 5. Boni MF, Lemey P, Jiang X, Lam TT, Perry BW, Castoe TA, et al. Evolutionary
482 origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19
483 pandemic. *Nat Microbiol*. 2020;5(11):1408-17.

484 6. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick L, Rattigan
485 SM, et al. A systematic review of antibody mediated immunity to coronaviruses:

- 486 antibody kinetics, correlates of protection, and association of antibody responses with
487 severity of disease. medRxiv. 2020:2020.04.14.20065771.
- 488 7. Pecora ND, Zand MS. Measuring the Serologic Response to Severe Acute
489 Respiratory Syndrome Coronavirus 2: Methods and Meaning. Clin Lab Med.
490 2020;40(4):603-14.
- 491 8. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic Comparison
492 of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-
493 CoV. Viruses. 2020;12(2).
- 494 9. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al. Coronavirus as a
495 possible cause of severe acute respiratory syndrome. Lancet. 2003;361(9366):1319-25.
- 496 10. Monto AS, DeJonge PM, Callear AP, Bazzi LA, Capriola SB, Malosh RE, et al.
497 Coronavirus Occurrence and Transmission Over 8 Years in the HIVE Cohort of
498 Households in Michigan. J Infect Dis. 2020;222(1):9-16.
- 499 11. New York State Coronavirus Tracker [Available from:
500 <https://coronavirus.health.ny.gov/home>.
- 501 12. Administration USFaD. Individual EUAs for Serology and Other Adaptive Immune
502 Response Tests for SARS-CoV-2 2021 [Available from: [https://www.fda.gov/medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2#individual-serological)
503 [devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-](https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2#individual-serological)
504 [devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-](https://www.fda.gov/medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2#individual-serological)
505 [sars-cov-2#individual-serological](https://www.fda.gov/medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2#individual-serological).

- 506 13. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al.
507 COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in
508 Saliva. *J Clin Microbiol.* 2020;59(1).
- 509 14. Sholukh AM, Fiore-Gartland A, Ford ES, Hou Y, Tse LV, Lempp FA, et al.
510 Evaluation of SARS-CoV-2 neutralization assays for antibody monitoring in natural
511 infection and vaccine trials. *medRxiv.* 2020.
- 512 15. Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M,
513 et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *medRxiv.*
514 2020:2020.03.17.20037713.
- 515 16. Lee WT, Girardin RC, Dupuis AP, Kulas KE, Payne AF, Wong SJ, et al.
516 Neutralizing Antibody Responses in COVID-19 Convalescent Sera. *J Infect Dis.*
517 2021;223(1):47-55.
- 518 17. Hicks J, Klumpp-Thomas C, Kalish H, Shunmugavel A, Mehalko J, Denson JP, et
519 al. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal
520 Betacoronaviruses. *J Clin Immunol.* 2021:1-8.
- 521 18. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf
522 D, et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and
523 Associations with Age and Disease Severity. *Cell.* 2020.
- 524 19. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.*
525 2021;184(4):861-80.

- 526 20. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, et al.
527 Correlates of protection against SARS-CoV-2 in rhesus macaques. *Nature*.
528 2021;590(7847):630-4.
- 529 21. Atyeo C, Fischinger S, Zohar T, Slein MD, Burke J, Loos C, et al. Distinct Early
530 Serological Signatures Track with SARS-CoV-2 Survival. *Immunity*. 2020;53(3):524-
531 32.e4.
- 532 22. Ng KW, Faulkner N, Cornish GH, Rosa A, Harvey R, Hussain S, et al.
533 Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*.
534 2020;370(6522):1339-43.
- 535 23. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, et al. Changes in
536 SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of
537 Infections in Population-Based Seroprevalence Studies. *J Virol*. 2021;95(3).
- 538 24. Gupta A, Malhotra Y, Patil U, Muradas AR, Lee WT, Krammer F, et al. In Utero
539 Vertical Transmission of Coronavirus Disease 2019 in a Severely Ill 29-week Preterm
540 Infant. *AJP Rep*. 2020;10(3):e270-e4.
- 541 25. Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to
542 SARS-CoV-2 in patients of novel coronavirus disease 2019. *medRxiv*.
543 2020:2020.03.02.20030189.
- 544 26. Sun B, Feng Y, Mo X, Zheng P, Wang Q, Li P, et al. Kinetics of SARS-CoV-2
545 specific IgM and IgG responses in COVID-19 patients. *Emerg Microbes Infect*.
546 2020;9(1):940-8.

- 547 27. Yang HS, Racine-Brzostek SE, Lee WT, Hunt D, Yee J, Chen Z, et al. SARS-
548 CoV-2 antibody characterization in emergency department, hospitalized and
549 convalescent patients by two semi-quantitative immunoassays. Clin Chim Acta.
550 2020;509:117-25.
- 551 28. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al.
552 Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19
553 disease and unexposed individuals. Cell. 2020.
- 554 29. Rosenberg ES, Tesoriero JM, Rosenthal EM, Chung R, Barranco MA, Styer LM,
555 et al. Cumulative incidence and diagnosis of SARS-CoV-2 infection in New York. Ann
556 Epidemiol. 2020;48:23-9.e4.
- 557 30. Wong SJ, Demarest VL, Boyle RH, Wang T, Ledizet M, Kar K, et al. Detection of
558 human anti-flavivirus antibodies with a west nile virus recombinant antigen microsphere
559 immunoassay. J Clin Microbiol. 2004;42(1):65-72.

560

561 **10. Figure Legends**

562 Figure 1 **Cross-reactivity between SARS-1 and SARS CoV-2 Nucleocapsid and**
563 **Spike antigens.** Sera from nonimmune or SARS-CoV-1-immunized
564 guinea pigs (*A,D*), a COVID-19 convalescent individual (*B,E*) or a panel of
565 sera from COVID convalescent individuals (*C,F*) were diluted and
566 measured in a MIA for total binding antibodies against the Nucleocapsid
567 (*top row*) and Spike antigens (*bottom row*) from either SARS-1 or SARS-
568 CoV-2. Binding activity is indicated by the median fluorescence intensities
569 (MFI).

570

571 Figure 2 **Determination of NYS SARS MIA specificity.** (*A*) Serum specimens
572 collected in 2009 from healthy blood donors (American Red Cross in
573 Syracuse, NY, and New York Blood Center in New York City, NY),
574 representing pre-COVID samples or (*B*) specimens collected in 2020 from
575 hospitalized SARS-CoV-2 RT-PCR negative individuals with molecular
576 determination of infection with non-SARS-CoV-2 respiratory viruses; or (*C*)
577 specimens collected in 2020 from COVID-19 convalescent individuals were
578 assessed using the NYS SARS MIA (SARS-1 N antigen target) for total
579 antibody reactivity. Shown are results of individual samples. On the far right
580 is a bar showing the reported interpretative results of (*blue*) Reactive, (*Red*)
581 Indeterminate or (*gray*) Nonreactive.

582

583 **Figure 3 Detection of N antigen reactivity by MIA.** Serum specimens from
584 individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and
585 reported symptom onset dates were assessed for total antibodies to the
586 SARS-1 N antigen. Each point represents the reactivity of a single
587 individual with the mean MFI of the group at each time point indicated by a
588 black bar. The gray bar at the top left indicates the data accumulated for the
589 initial submission of the MIA for FDA EUA with assay sensitivity determined
590 as the percentage of specimens reactive at ≥ 6 SD above the cutoff.

591

592 **Figure 4 Reactivity to different SARS-CoV-2 target antigens as determined by**
593 **MIA.** Serum specimens from individuals with SARS-CoV-2 infections,
594 confirmed using RT-PCR, and reported symptom onset dates were
595 assessed for total antibodies to the SARS-CoV-1 spike antigen or different
596 SARS-CoV-2 target antigens (Nucleocapsid, complete spike, and separate
597 spike components (RBD, S1 subunit, S2 subunit). Reactivity is expressed
598 as an Index value where a value of 1.0 is 3 SD above the cutoff for the
599 individual target antigen and positivity being the Index value that is ≥ 6 SD
600 above the cutoff for the individual target antigen. (A) The reactivity in the
601 same sera to Nucleocapsid and RBD antigens at different times after onset
602 of symptoms shown for individuals or as a percent of the total sera (far right

603 panel). (B) Relative binding to multiplexed antigens in the sera of 10 COVID-
604 19 convalescent individuals (means + SD).

605

606 **Figure 5 Production of different antibody classes reactive with SARS-CoV-2**
607 **target antigens.** Serum specimens from individuals with SARS-CoV-2
608 infections, confirmed using RT-PCR, and reported symptom onset dates
609 were assessed for total antibody, IgM, IgG, and IgA antibodies to different
610 SARS-CoV-2 target antigens (Nucleocapsid, full spike, and separate spike
611 components (RBD, S1 subunit, S2 subunit). Shown are the percentages of
612 positive specimens for each class to the individual target antigens.

613

614 **Figure 6 Kinetics of different antibody class production in COVID-19**
615 **individuals.** Serum specimens from two individuals hospitalized with
616 SARS-CoV-2 infections were collected on different days after reported
617 symptom onset dates and were assessed for IgG1, IgG2, IgG3, and
618 antibodies to different SARS-CoV-2 target antigens (Nucleocapsid, and
619 separate spike components (RBD, S1 subunit, S2 subunit). Shown are the
620 percentages of positive specimens for each class to the individual target
621 antigens.

622

623 Figure 7 **Production of different IgG subclasses reactive with SARS-CoV-2**
624 **target antigens in the MIA.** Serum specimens from individuals with SARS-
625 CoV-2 infections, confirmed using RT-PCR, and reported symptom onset
626 dates were assessed for IgG1, IgG2, IgG3, and IgG4 antibodies to SARS-
627 CoV-2 nucleocapsid, spike antigen and spike components: RBD, S1, and
628 S2 target antigens. Shown are the percentages of positive specimens for
629 each class to the individual target antigens









Figure 1






Figure 2




Figure 3







Figure 4







Figure 5





Figure 6







Figure 7

	Non-Reactivity (95%CI) in the MIA (N plus RBD)			
	<i>Ig</i>	<i>IgM</i>	<i>IgG</i>	<i>IgA</i>
Blood Donors	240/244 (98.4%) (95.9-99.4)	248/257 (96.5%) (93.5-98.2)	254/257 (98.8%) (96.6-99.7)	182/186 (97.8%) (94.6-99.2)
Diverse Group of Analytes	77/78 (98.7%) (93.1-99.9)	74/78 (94.9%) (87.5-98.0)	76/78 (97.4%) (91.1-99.5)	77/78 (98.7%) (93.1-99.9)

Table 1. Determination of MIA Specificity. Sera collections were used to evaluate total antibody (Ig) or isotype-specific binding to either the SARS-CoV-2 N protein or the RBD of the spike protein in a multiplexed MIA: (top) 182-257 serum samples collected in 2009 from healthy blood donors (American Red Cross in Syracuse, NY, and New York Blood Center in New York City, NY), representing pre-COVID samples; (bottom) 78 serum samples with known antibody reactivity to a diverse group of viral pathogens (Chikungunya, dengue, HCV, HIV, measles, mumps, rubella, VZV, West Nile virus, herpes simplex, Zika virus, enteroviruses, HBV, cytomegalovirus, Epstein Barr, Eastern Equine Encephalitis, and Yellow Fever viruses), as well as sera with Antinuclear antibodies and Rheumatoid Factor. Shown are the numbers (percentages) of MIA negative/total specimens and the 95% Confidence Intervals. “Negative” means non-reactive to both target antigens in the specimen; “indeterminate” means indeterminate to one target antigen and indeterminate or non-reactive to the other target antigen in the specimen. For this analysis, indeterminates and negatives are counted together, using a threshold of 6 SD above the mean MFI of 92 normal sera to determine positivity.

Total Antibody binding to N plus RBD						
Days from onset	Samples tested (N)	RT-PCR result	NY SARS-CoV MIA Result as Compared to PCR			Sensitivity (95%CI)
			Positive	Indeterminate	Negative	
7 – 15	48	Pos	23	7	18	23/48 47.9% (34.47% - 61.67%)
16 – 25	17	Pos	14	0	3	14/17 82.4% (58.97% - 93.81%)
26 – 30	28	Pos	27	1	0	27/28 96.4% (82.29% - 99.82%)
Total	93					

Table 2. Determination of MIA Sensitivity. A total of 93 serum specimens from individuals with SARS-CoV-2 infections, confirmed using RT-PCR, and reported symptom onset dates were assessed for total antibodies to the SARS-CoV-2 Nucleocapsid antigen and the RBD. A positive specimen is ≥ 6 SD above the cutoff for either one of the target antigens; an indeterminate is ≥ 3 SD above the cutoff for either or both of the target antigens; a negative is a sample with no reactivity to either target antigen. Sensitivity at different period post symptom onset is shown on the right as the number of MIA-positive specimens/total specimens tested.

Convalescent Serum Specimens	Number	Percentage
Total Tested	8659	100
N and RBD (Both Reactive or Indeterminate in the same sample)	7980	92.2
N (Reactive or Indeterminate) with RBD (Nonreactive)	365	4.2
RBD (Reactive or Indeterminate) with N (Nonreactive)	101	1.2
Both antigens Nonreactive	238	2.7
One or both antigen Indeterminate (<i>clinical*</i>)	192	2.2
Using N only, Positive @6 SD (<i>clinical*</i>)	7986	92.2
Using N only, Positive @3 SD	8304	95.9
Using N and RBD**, Positive @6 SD (<i>clinical*</i>)	8219	94.9
Using N and RBD**, Positive @3 SD	8411	97.1

Table 3. Reactivity to the SARS-COV-2 N and RBD antigens. 8659 serum specimens from convalescent COVID-19 donors who were at least 14 days removed from symptom onset were tested using the MIA for total antibody reactivity to the SARS-COV-2 and RBD antigens. A reactive specimen is ≥ 6 SD above the cutoff; an indeterminate is ≥ 3 SD above the cutoff. The bottom four rows indicate assay reported results calculated to show positivity at 3SD or 6 SD thresholds and shows the effect of using the single N target Ag versus both target Ags. * Threshold used for reporting “Reactive” specimens in diagnostic assays. **One or both target Ags reactive.